Nonalcoholic steatohepatitis (NASH) is the most prevalent cause of chronic liver disease in the Western world. However, an optimum therapy for NASH is yet to be established, mandating more in-depth investigation into the molecular pathogenesis of NASH to identify novel regulatory molecules and develop targeted therapies. Here, we unravel a unique function of astrocyte elevated gene-1(AEG-1)/metadherin in NASH using a transgenic mouse with hepatocyte-specific overexpression of AEG-1 (Alb/AEG-1) and a conditional hepatocyte-specific AEG-1 knockout mouse (AEG-1 DHEP ).
N onalcoholic fatty liver disease, the most common cause of chronic liver disease in the Western world leading to cirrhosis and hepatocellular carcinoma, is characterized by initial accumulation of triglycerides (TGs) in hepatocytes (hepatic steatosis) with subsequent nonalcoholic steatohepatitis (NASH). (1, 2) The pathogenesis of NASH includes an initial metabolic disturbance that increases the influx of free fatty acids (FFAs) and de novo lipogenesis, followed by inflammation, oxidative stress, and lipid peroxidation. (3) The molecular players regulating these events are gradually being identified, leading to evaluation of multiple strategies in clinical trials. (1) However, an optimum therapy is yet to be established, indicating that more comprehensive understanding of the molecular mechanism of NASH is urgently needed to develop effective therapeutic strategies.
Astrocyte elevated gene-1 (AEG-1), also known as metadherin (MTDH) and LYRIC, is a pleiotropic protein with a diverse array of functions. (4) AEG-1 is fundamentally required for the activation of the nuclear factor jB (NF-jB) pathway, a pivotal determinant of inflammation, and AEG-1 regulates NF-jB at multiple levels. (5) (6) (7) (8) Lipopolysaccharide-induced NF-jB activation is markedly abrogated in AEG-1 knockout (AEG-1KO) hepatocytes and macrophages, and AEG-1KO mice show resistance to aging-associated inflammation. (9) An essential component of AEG-1 function is its ability to interact with, and inhibit the function of, retinoid X receptor (RXR). (10) RXR heterodimerizes with nuclear receptors, including liver X receptor (LXR), peroxisome proliferator-activated receptor (PPAR), and farnesoid X receptor (FXR), and regulates corresponding ligand-dependent gene transcription. (11) Cholesterol metabolites, fatty acid derivatives, and bile acids serve as endogenous ligands for LXR, PPAR, and FXR, respectively, which play an important role in regulating lipid metabolism, hence NASH. (12) These transcription factors exert opposing effects, for example, LXR promotes NASH by augmenting de novo lipogenesis, whereas PPARa inhibits NASH by augmenting fatty acid b-oxidation. (13, 14) Interaction between AEG-1 and RXR in the nucleus blocks coactivator recruitment, thereby abrogating ligand-induced gene transcription. (10) Interaction of cytoplasmic AEG-1 with RXR blocks RXR nuclear translocation and also induces RXR phosphorylation and hence inactivation. (10) We generated a transgenic mouse with hepatocytespecific overexpression of AEG-1 (Alb/AEG-1) to analyze its oncogenic function. (15) Interestingly, we observed that Alb/AEG-1 mice develop spontaneous NASH, and in the present article we further show that a hepatocyte-specific conditional AEG-1KO mouse (AEG-1 DHEP ) is resistant to high-fat diet (HFD)-induced NASH, and human NASH patients show overexpression of AEG-1. We demonstrate that AEG-1 promotes NASH by regulating the function of nuclear receptors, promoting translation of lipogenic enzymes and activating inflammation. We also document inhibition of AEG-1 as a potential strategy to protect from NASH. These findings identify AEG-1 as a novel regulator of NASH onset and progression, and suggest that AEG-1 inhibition in the liver might serve as an effective interventional therapeutic to halt NASH progression.
Materials and Methods

MICE
Generation and characterization of a hepatocytespecific AEG-1 transgenic mouse (Alb/AEG-1) in B6/CBA background have been described. (15) Floxed AEG-1 mice (AEG-1 fl/fl ) in C57BL/6 background (9) was crossed with Alb/Cre (Jackson Laboratories, Bar Harbor, ME) mice to generate AEG-1 DHEP mice. Mice were fed regular chow. For HFD experiments, 8-week-old mice were fed a high-fat and cholesterolcontaining diet (TD. 88137; Harlan, Indianapolis, IN) for 20-22 weeks. This diet contains 0.2% total cholesterol and 21% total fat by weight, which provides 42% kcal (4.5 kcal/g). All animal studies were approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth University (Richmond, VA).
PATIENT SAMPLES
Liver biopsy samples were collected from normal livers (biopsied for ruling out differential diagnosis; n 5 32) and NASH patients (n 5 21). Stage 1 and 2 NASH patients, according to NASH Clinical Research Network modified Brunt methodology, (16) were selected and patients with bridging fibrosis or cirrhosis were excluded (Supporting Table S1 ). The institutional review board of New York Methodist Hospital approved these studies.
TISSUE CULTURE
Primary mouse hepatocytes (PMHs) were isolated and cultured as described. (15) Telomerase immortalized human hepatocytes Hc3716-hTERT are a kind gift from Dr. Tahara. (17) HepG3 and QGY-7703 cells were cultured as described. (18) Generation and characterization of Hep-pc-4 (control clone) and Hep-AEG-1-14 (a COOH-terminal hemagglutinin-tagged AEG-1 overexpressing clone) in HepG3 background, and Hep-Consh (HepG3 clone stably expressing control short hairpin RNA [shRNA]) and Hep-AEG-1sh (HepG3 clone stably expressing AEG-1 shRNA), have been described. (18, 19) 
STATISTICAL ANALYSIS
Data are represented as the mean 6 SEM and analyzed for statistical significance using one-way analysis of variance followed by Newman-Keuls test as a posthoc test. A P value of <0.05 was considered as significant. Overexpression of AEG-1 in NASH patients was analyzed by Pearson's v 2 test.
Results
Alb/AEG-1 MICE DEVELOP SPONTANEOUS NASH
Analysis of liver sections of 6-month-old wild-type (WT) and Alb/AEG-1 littermates showed increased fat droplets in hematoxylin and eosin (H&E) staining, increased fibrosis (assayed by a-smooth muscle actin [a-SMA], collagen I, and picrosirius red staining), and increased inflammation (F4/80 staining for infiltrated macrophages) in Alb/AEG-1 versus WT mice, indicating features of NASH ( Fig. 1A and Supporting Fig. S1A-C) . Levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) were significantly higher in Alb/AEG-1 serum than in WT serum in both sexes, except for IL-6 which did not show an increase in female Alb/AEG-1 mice and might be explained by inhibition of IL-6 by estrogen (Fig.  1B) . (20) Serum liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (Alk Phos), total TGs and FFAs, and hepatic TG and cholesterol levels were significantly higher in Alb/AEG-1 mice compared to WT (Fig.  1C-E) . Total TG level in conditioned media from an AEG-1-overexpressing clone of human HCC cell line HepG3 (Hep-AEG-1-14) was significantly higher compared to control clone Hep-PC-4, indicating that in vivo observations in mice are maintained in human cell lines (Supporting Fig. S1D ). (18) Steatosis is often associated with insulin resistance.
(21) Indeed, basal blood glucose level was significantly increased in Alb/ AEG-1 over WT mice (Fig. 1F, top) . Glucose tolerance test (GTT) revealed impaired glucose management in Alb/AEG-1 mice in which blood glucose level remained significantly higher 2 hours after the initial glucose injection versus WT, further indicating reduced insulin sensitivity (Fig. 1F, bottom) .
AEG OVEREXPRESSION IN THE LIVER IS LINKED WITH THE PRESENCE OF NASH
To further evaluate the role of AEG-1 in NASH progression, we examined the response of WT and Alb/AEG-1 littermates to 20 weeks of HFD feeding. A significant increase in liver weight and liver enzymes and elevated levels of TG, cholesterol, and HDL and markedly elevated levels of LDL and VLDL were detected in sera of chow-and HFD-fed Alb/AEG-1 mice versus WT ( Fig. 2A,B) . Although HFD feeding induced development of steatosis in WT mice, in Alb/ AEG-1 mice the steatotic phenotype was more pronounced with large fat droplets, collagen bands (indicated by picrosirius staining), and lobular inflammation (indicated by neutrophil infiltration; Fig.  2C and Supporting Fig. S1B,E) . A significant increase in levels of mRNA of inflammatory and fibrotic genes was observed in livers of chow-fed Alb/AEG-1 mice compared to WT, which was further augmented upon feeding HFD (Fig. 2D) . Liver sections from WT mice that developed HFD-induced steatosis showed a marked increase in AEG-1 expression compared to WT chow-fed controls ( Fig. 2E and Supporting  Fig. S1F ).
To evaluate the status of AEG-1 in livers of NASH patients, AEG-1 expression was analyzed by immunohistochemistry in biopsy samples of 32 normal, non-NASH-afflicted livers (biopsied for ruling out differential diagnosis) and 21 livers with NASH. Significant overexpression of AEG-1 was detected in NASH patients compared to non-NASH individuals (Pearson's v 2 test: P < 0.0001; Fig. 3A ,B; Supporting Table S1 ). We next checked which factors induce AEG-1 overexpression in NASH. Treatment with palmitate did not induce AEG-1 (data not shown) in PMHs and Hc3716 immortalized human hepatocytes. (17) However, treatment with tumor necrosis factor alpha (TNFa) and IL-1b significantly induced AEG-1 mRNA in both cell types, which could be inhibited by BMS-3445541, an inhibitor of kappa B kinase inhibitor (IKK), indicating a potential role of NF-jB in mediating inflammatory cytokine-induced AEG-1 expression (Supporting Fig. S1G ). Taken together, these findings provide evidence of a positive feedback , liver enzymes and total TG (C), and FFA (D) levels were measured in sera and hepatic TG and cholesterol levels (E) were analyzed in 6-month-old male littermates (n 5 6/group). (F) Blood glucose level was measured either under basal condition (top) or after GTT (bottom). Male mice were used (n 5 12/group). For graphs, data represent mean 6 SEM. *P < 0.01; **P < 0.001. Abbreviation: FFPE, formalin-fixed paraffin-embedded.
relationship, wherein NF-jB and AEG-1 regulate each other, fostering a chronic inflammatory state.
AEG-1 DHEP MICE ARE RESISTANT TO HFD-INDUCED NASH
To directly investigate whether the presence of AEG-1 in the hepatocyte is essential to NASH initiation, we generated a hepatocyte-specific conditional AEG-1 KO mouse (AEG-1 DHEP ), with complete loss of AEG-1 in hepatocytes (Supporting Fig.  S2A -C). Male AEG-1 DHEP mice showed marked resistance to NASH development following 22 weeks on an HFD (Fig. 3C) . Analysis of liver sections revealed decreased fat droplet accumulation, collagen I and F4/80 staining, and neutrophil infiltration in AEG-1 DHEP mice compared to their AEG-1 fl/fl littermates ( Fig. 3C and Supporting Fig. S2D ), indicating an overall reduction in the phenotypic hallmarks of NASH. Furthermore, liver weight, serum levels of liver enzymes, hepatic TG, and cholesterol levels and mRNA levels of inflammatory and fibrotic genes were also dramatically reduced in livers of HFD-fed AEG-1 DHEP mice compared to AEG-1 fl/fl mice ( Fig. 3D-F ). These findings indicate that livers of AEG-1 DHEP mice are protected from HFD-induced NASH and suggest that AEG-1 expression is required for initiation and progression of the disease.
AEG-1 REGULATES PPARa FUNCTION
To thoroughly compare the differences in the gene expression profiles between WT and Alb/AEG-1 hepatocytes, an Affymetrix oligonucleotide microarray analysis was performed using WT and Alb/AEG-1 hepatocytes harvested from 12-week-old mice. Using a false discovery rate of 0 (q-value, 0%) as the cutoff, 810 genes showed differential change, 366 genes showed up-regulation, and 444 genes showing downregulation in Alb/AEG-1 hepatocytes compared to WT (a complete list of differentially regulated genes is available in GSE46701). Genes regulating lipid biosynthesis and transport, lipid oxidation, inflammatory cytokines, and adipokines were significantly modulated in Alb/AEG-1 hepatocytes, consistent with the observed phenotypes ( Table 1) . Several of these genes were then selected from the data set and independently validated by Q-RT-PCR and western blotting (Fig.  4A , left panel, and 4B, left panel). All differentially changed genes were analyzed using Ingenuity Pathway Analysis software to identify the upstream regulators the activation or inhibition of which might lead to alterations in downstream genes. A z-score >2 indicates activation and a score of <-2 indicates inhibition. The most robust inhibition in Alb/AEG-1 hepatocytes was observed for genes that are regulated by PPARa, PPARc, and PXR with very significant P value and a z-score of <-2 (Fig. 4C, top panel) . Although inhibition of LXRa, LXRb, and constitutive androstane receptor (CAR) showed a significant P value, the z-score was >-2. These findings suggest that there is preferential inhibition of PPAR and PXR target genes in Alb/AEG-1 hepatocytes compared to WT hepatocytes. Reduced expression of CAR and LXR target genes was also observed. However, overall Abbreviations: ACC1, acetyl-CoA carboxylase 1; Acly, ATP citrate lyase; APOB, apolipoprotein B; Apoc2, apolipoprotein C2; Dgat1, diacylglycerol O-acyltransferase 1; EF1a, elongation factor-1 alpha; Elovl3, ELOVL fatty acid elongase 3; Fabp1, fatty acid binding protein 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Hmgcr, 3-hydroxy-3-methylglutaryl-CoA reductase; NS, nonspecific; Pltp, phospholipid transfer protein; RAPTOR, regulatory associated protein of mTOR complex 1; RLU, relative luciferase units; RPL, ribosomal protein L; Slc27a2, solute carrier family 27 member 2; Spp1, secreted phosphoprotein 1; Srebf1, sterol regulatory element binding transcription factor 1; STAT3, signal transducer and activator of transcription 3.
the magnitude of inhibition and the number of genes were not sufficient to attain a significant z-score. AEG-1 plays a fundamental role in regulating NF-jB and inflammation. (6, 9) In concordance, the most robust activation was observed in upstream regulators, such as Toll-like receptor (TLR) 4, TLR3, IL-1b, TNFa, IL-6, and NF-jB complex, all of which are critical components involved in inflammatory signaling (Fig. 4C,  top panel) . We performed RNA sequencing (RNASeq) analysis on liver samples of chow-fed 12-weekold AEG-1 fl/fl and AEG-1 DHEP mice. With a P-value cutoff of <0.05, 868 genes showed differential regulation (the complete list is available in GSE85098), a subset of which were then validated (Fig. 4A, 1 hepatocytes (Fig. 4D) or AEG-1 fl/fl and AEG-1 DHEP livers (Supporting Fig. S3A ), further indicating an important role of AEG-1 in regulating the PPARa signaling pathway. We therefore focused our studies on AEG-1-mediated regulation of PPARa activity.
We checked PPRE (PPAR response element) luciferase (luc) activity in WT and Alb/AEG-1 hepatocytes as well as Hep-pc-4 and Hep-AEG-1-14 cells. To stimulate PPARa activity, cells were treated with synthetic ligands of PPARa, CP775146, and fenofibrate. Both basal-and ligand-dependent PPRE-luc activity were significantly inhibited upon AEG-1 overexpression when compared to control in the presence or absence of PPARa expression plasmid (Fig. 4E) . Similarly, basal-and liganddependent PPRE-luc activity was significantly less in QGY-7703 cells when compared to HepG3 cells, expressing high and low levels of endogenous AEG-1, respectively (Supporting Fig. S3B ). Expression of PPARa and its coactivator, PPARc coactivator 1 alpha (PGC1a), was down-regulated in Alb/AEG-1 hepatocytes versus WT as well as Hep-AEG-1-14 cells versus Hep-pc-4 cells (Fig. 4F and Supporting  Fig. S2C ). Down-regulation of PPARc and PPARa coactivator Lipin1 was also observed in Alb/AEG-1 hepatocytes over WT (Supporting Fig. S3C ). It has been shown that Lipin1 acts as an inducible amplifier of the PPARa/PGC1a pathway in hepatocytes, (22) and AEG-1-mediated inhibition in Lipin1 would indirectly lead to further abrogation of PPARa signaling.
We next analyzed expression levels of PPARa target genes that regulate b-oxidation of fatty acids in WT and Alb/AEG-1 hepatocytes. To evaluate the mitochondrial b-oxidation pathway, we analyzed carnitine palmitoyltransferase 1a (Cpt1a), the rate-limiting enzyme in the carnitine-dependent transport of fatty acids across the mitochondrial membrane, and acylCoA dehydrogenase (Acad) l and Acadm, which catalyze the initial steps of fatty acid b-oxidation. (23) Peroxisomal b-oxidation was evaluated by analyzing acylCoA oxidase 1 (Acox1), the first enzyme in this pathway, and peroxisomal membrane protein 11A (Pex11a). (23) Both basal-and ligand-dependent induction of these genes was blunted in Alb/AEG-1 hepatocytes and augmented in AEG-1 -/-hepatocytes compared to controls (Fig. 5A,B) . Interestingly, expression of these genes was further suppressed in livers of HFD-fed Alb/AEG-1 mice when compared to HFD-fed WT mice (Fig. 5C) . Levels of bhydroxybutyrate (3 0 -HB), a product of fatty acid (FA) oxidation (FAO), were significantly lower in sera of Alb/AEG-1 mice versus WT and in Alb/AEG-1 hepatocytes compared to WT hepatocytes (Fig. 5D ), further suggesting reduced rate of b-oxidation when AEG-1 is overexpressed. To directly investigate the differences in rates of FA b-oxidation, we measured products of FA b-oxidation in fresh liver homogenates using 14 C-palmitate. (24) Acetyl-CoA, generated by boxidation, enters the tricarboxylic acid cycle to generate CO 2 .
14 C-palmitate that does not get oxidized forms acid-soluble metabolites (ASMs). Reduced production of these intermediates indicated a significant decrease in the rate of FA b-oxidation in livers of Alb/AEG-1 versus WT mice (Fig. 5E) .
To directly evaluate the relationship between AEG-1 expression and PPARa activity, we examined recruitment of RXRa/PPARa heterodimer and coactivator steroid receptor coactivator-1 (SRC-1) on Acox1 and Cpt1a promoter upon CP775146 treatment in WT and Alb/AEG-1 hepatocytes by chromatin immunoprecipitation (ChIP) assay. Previous ChIP sequencing studies have documented binding of PPARa in promoters of Acox1 and Cpt1a (Supporting Fig. S3D ). (25) Additionally, we generated luc reporter vectors under control of Acox1 and Cpt1a promoter amplicons and created mutants of these reporter vectors with point mutations in PPRE. In WT hepatocytes, both the promoter constructs showed increased activity upon cotransfection of PPARa expression construct and treatment with PPARa agonists, which was lost in the mutant constructs (Supporting Fig. S3E ). Upon confirmation that these genes are bona-fide PPARa target genes, we proceeded with our ChIP assay. A significant decrease in recruitment of RXRa/PPARa heterodimer was observed in Alb/AEG-1 hepatocytes compared to WT hepatocytes (Fig. 5F ). This decrease might be attributed to a decrease in total PPARa and decrease in nuclear RXRa in Alb/AEG-1 livers given that cytoplasmic AEG-1 can interact with RXR and prevent RXR nuclear translocation. (10) However, a marked inhibition of SRC-1 recruitment was observed in Alb/AEG-1 hepatocytes upon ligand treatment, confirming that AEG-1 overexpression interferes with coactivator recruitment.
AEG-1 REGULATES LIPOGENIC ENZYMES AT A TRANSLATIONAL LEVEL
Inhibition of FA b-oxidation might lead to accumulation of TG and FA, contributing to steatosis.
However, one important component of NASH is de novo lipogenesis, and a key enzyme in this pathway is fatty acid synthase (Fasn). LXR transcriptionally regulates Fasn by binding to LXR response element in its promoter. (26) LXR also regulates sterol regulatory element-binding protein-1 (SREBP-1), which controls transcription of lipogenic genes. (27) As described earlier, upstream analysis identified a trend involving a decrease in LXR/RXR signaling in Alb/AEG-1 hepatocytes, which did not attain a significant z-score. Additionally, if LXR function is inhibited, there will be a decrease in Fasn resulting in decrease lipogenesis. However, no differences in Fasn mRNA levels were observed either by RNA-Seq analysis of AEG-1 S-methionine for the indicated time points and 500 lg of protein per sample was used to immunoprecipitate FASN. Top, autoradiogram of the immunoprecipitates. Bottom, Coomassie blue (CB) stain of 5% of input. (E) WT and Alb/AEG-1 hepatocytes were either untreated or treated with CP775146 (2.5 lM), fenofibrate (5 lM), C75 (10 lg/mL), or cerulenin (10 lg/mL) and TG level was measured. Data represent mean 6 SEM of three independent experiments. **P < 0.001 between untreated (UT) groups; # P < 0.05 between untreated and treated Alb/ AEG-1 hepatocytes. (F) Cartoon depicting the molecular mechanism by which AEG-1 is induced in NASH and AEG-1 promotes NASH. Abbreviations: CP, CP775146; DG, diglyceride; EF1a, elongation factor-1 alpha; MG, monoglyceride.
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and AEG-1 -/-livers or by Affymetrix microarray analysis of Hep-pc4 and Hep-AEG-1-14 cells. (9, 18) Fasn mRNA levels were also unchanged between WT and Alb/AEG-1 hepatocytes, and AEG-1 fl/fl and AEG-1 DHEP livers in microarray and RNA-Seq analyses, respectively, as were levels of stearoyl-CoA desaturase 1 (SCD1), another LXR target gene. These data were confirmed by Q-RT-PCR (Fig. 4A) . We also did not observe any change in the total and cleaved forms of SREBP-1 in Alb/AEG-1 and AEG-1 DHEP livers compared to controls (Fig. 6A) . These findings argue that LXR activity may not be affected by AEG-1 status. However, there was a significant increase in Alb/ AEG-1 and a decrease in AEG-1 DHEP livers in FASN protein levels compared to controls (Fig. 6A) . Additionally, a dual color two-dimensional gel electrophoresis comparing HepG3 clone stably expressing control shRNA (Hep-Consh) and HepG3 clone stably expressing AEG-1 shRNA (Hep-AEG-1sh) showed a marked decrease in FASN protein levels in Hep-AEG-1sh cells compared to Hep-Consh, although Fasn mRNA levels remained unchanged (Supporting Fig. S4 ). To confirm that the increase in lipogenic enzymes indeed contributes to de novo lipogenesis, 14 C-acetate incorporation in fresh liver homogenates was performed followed by analysis of lipid fractions. A significant and robust increase in TG and phospholipid (PL), and small increases in monoglyceride and diglyceride, FFA, and cholesterol ester (CE) were observed in Alb/AEG-1 versus WT livers (Fig. 6B) .
AEG-1 is known to regulate gene expression at the translational level. (28) We therefore analyzed association of Fasn mRNA to polysomes. Polysomal fractions were collected from WT and Alb/AEG-1 hepatocytes, RNA was extracted from each fraction and an equal amount of RNA from each fraction was subjected to complementary DNA synthesis and Taqman Q-RT-PCR for Fasn. The mean cycle threshold (CT) value for Fasn amplification was significantly lower in Alb/ AEG-1 hepatocytes compared to WT hepatocytes, indicating that AEG-1 preferentially helps Fasn mRNA associate with polysomes and thereby facilitates translation (Fig. 6C) . To further confirm these findings, we analyzed de novo FASN protein synthesis by labeling WT and Alb/AEG-1 hepatocytes with 35 S-methionine and then temporally analyzing FASN protein level by immunoprecipitation. In Alb/AEG-1 hepatocytes, de novo FASN protein could be detected as early as 1 hour after addition of 35 S-methionine, which continued to increase robustly until 4 hours, whereas in WT hepatocytes it was not detected until 4 hours at a substantially lower level (Fig. 6D) .
To assess the relative contribution of the identified pathways to increased TG level, we treated WT and Alb/AEG-1 hepatocytes with PPARa activators CP775146 and fenofibrate and FASN inhibitors C75 and cerulenin. Activation of PPARa and inhibition of FASN significantly reduced TG level in Alb/AEG-1 hepatocytes compared to control (Fig. 6E) . Additionally, PPARa activation resulted in significant increase in 3 0 -HB levels in Alb/AEG-1 versus WT hepatocytes (Supporting Fig. S3F ). Collectively, our findings reveal that inhibition of PPARa, translational up-regulation of FASN, and NF-jB activation might work in concert to mediate AEG-1-induced NASH (Fig. 6F) .
NANOPARTICLE-DELIVERED AEG-1 SMALL INTERFERING RNA PROTECTS FROM HFD-INDUCED STEATOSIS
We have developed liver-targeted nanoplexes by conjugating polyamidoamine (PAMAM) dendrimers with polyethylene glycol (PEG) and galactose lactobionic acid (PAMAM-PEG-Gal), which were complexed with AEG-1 small interfering RNA (siRNA; PAMAM-AEG-1si; Fig. 7A , top) and documented its therapeutic utility in the context of cancer. (29) Cationic PAMAM complexes and compacts siRNA, PEG increases stability and increases circulation time, and the galactose (lactobionic acid) binds to asialoglycoprotein receptors that are up-regulated on liver cells. (29) We have now generated PAMAM-AEG-1si specific for mouse AEG-1 and checked its efficacy in inhibiting HFD-induced steatosis. WT C57BL/6 mice (n 5 10/group) were fed HFD for a total of 8 weeks. After 2 weeks of feeding HFD, mice were injected intravenously with PAMAM-siCon (control scrambled siRNA conjugated with PAMAM-PEGGal) or PAMAM-AEG-1si (5 lg of siRNA, conjugated with PAMAM-PEG-Gal at a ratio of 10:1) twiceweekly for 4 weeks (Fig. 7A, bottom) . Mice were sacrificed 2 weeks after the last injection. PAMAM-AEG1si treatment resulted in significant knockdown of AEG-1 mRNA only in liver, but not in spleen and small intestine, confirming efficiency of liver-specific targeting (Fig. 7B) , which was also documented by immunohistochemistry (IHC) staining of liver sections for AEG-1 (Fig. 7C) . Treatment with PAMAM-AEG-1si resulted in profound inhibition of HFD-induced steatosis (detected by H&E and Oil Red O staining), inflammation (detected by F4/80 staining), and fibrosis (detected by collagen I staining) compared to PAMAM-siCon ( Fig. 7C and Supporting Fig. S5 ). Liver weight, serum liver enzymes, and hepatic TG and cholesterol levels were significantly less in the PAMAM-AEG-1si group versus the PAMAM-siCon group, indicating efficacy of treatment and protection from HFD-induced liver damage (Fig. 7D) . Compared to PAMAM-siCon, PAMAM-AEG-1si treatment resulted in significant increase in PPARa-target genes and decrease in FASN protein levels and NF-jB activation, as indicated by decreased p-p65 levels and Il6 mRNA (Fig. 7E,F) . Thus, targeting of AEG-1 in the liver might be a useful therapeutic intervention for NASH.
Discussion
Our present studies reveal that AEG-1 contributes to both arms of the NASH-inducing mechanism, de novo lipogenesis and inflammation. We observe upregulation of AEG-1 in livers of mice chronically fed HFD as well as in NASH patients. Accordingly, there is a vicious cycle where HFD feeding induces AEG-1 and AEG-1 overexpression further augments the consequences of HFD-feeding, resulting in aggravation and exacerbation of NASH development and progression. Inflammatory cytokines significantly induced AEG-1 mRNA expression in both mouse and human hepatocytes through the NF-jB pathway. Thus, HFD-induced inflammatory events might be both the cause and consequence of AEG-1 overexpression.
We document three potential mechanisms that collaborate in the development of spontaneous NASH in Alb/ AEG-1 mice: inhibition of PPARa function; translational regulation of FASN; and induction of inflammation (Fig. 6F) . AEG-1 interacts with and inhibits RXR function. (10) However, our current findings document that this inhibition of RXR by AEG-1 does not equally influence all RXR heterodimer partners. We observed significant inhibition of PPARa function affecting boxidation of FAs. However, LXR and FXR functions remained relatively unaffected. The mechanism underlying differential regulation of nuclear receptors by AEG-1 is a question that remains unclear. Coactivators contain multiple "LXXLL" motifs (SRC-1 and PGC1a contain three) with which they interact with both RXR and its heterodimer partner. (30) (31) (32) (33) AEG-1 contains only one LXXLL motif and our initial yeast two-hybrid assay to identify AEG-1 interacting proteins identified only RXR, but not other nuclear receptors, to interact with AEG-1. (10) The ability of AEG-1 to interact with other nuclear receptors apart from RXR and any potential mechanisms for preferential binding to specific nuclear receptors are essential points that will require further investigation. Whereas SRC-1 functions as a coactivator for a wide range of nuclear receptors, including PPAR and LXR, in the liver PGC1a serves as a coactivator mainly for PPAR. (30, 33, 34) It needs to be checked whether AEG-1 exerts preferential effect on recruitment of SRC-1 or PGC1a on nuclear receptors. In addition to inhibition of PPARa/RXR transcriptional activity, a significant decrease in levels of PPARa and its coactivators, PGC1a and Lipin1, was observed in Alb/AEG-1 livers. Thus, there might be additional mechanisms, regulated by AEG-1, that contribute to inhibition of PPARa.
Although AEG-1 can directly activate NF-jB, inhibition of PPARa might also activate NF-jB by relieving the inhibitory effect of PPARa on NF-jB by transrepression. (35) Thus, AEG-1 effect on NASH mechanistically parallels that of PPARa inhibition. What differentiates AEG-1 is its ability to regulate de novo lipogenesis; the underlying molecular mechanism of this process is complex. We observed neither activation of SREBP-1 nor changes in mRNA of LXR target genes, particularly Fasn and Scd1, key regulators of lipogenesis. However, we observed activation of SREBP-2 (Fig. 4B) , which might induce lipogenic enzymes, such as acetylCoA carboxylase alpha, at the mRNA level. (36) SREBP-2 promotes cholesterol synthesis and low-density lipoprotein (LDL) uptake. (37) Even though we did not observe any difference in HMGcoR (Fig. 4B) , a ratelimiting enzyme in cholesterol biosynthesis, at mRNA and protein levels, SREBP-2-mediated increased uptake might explain increased cholesterol, especially the marked increase in LDL, in Alb/AEG-1 mice. However, the molecular mechanism of the differential regulation of SREBP-2 by AEG-1 remains to be determined. Another important point to note is that even though there was robust activation of protein kinase B (Akt) in Alb/AEG-1 hepatocytes, no change was observed for activation of mammalian target of rapamycin (mTOR; Fig. 4B ), a master regulator of metabolism and translational control. (38) We observed a marked increase in FASN and other lipogenic enzymes at the protein level in Alb/AEG-1 livers. We also document that AEG-1 overexpression facilitated association of Fasn mRNA with polysomes. Moreover, increase in ribosomal proteins (Fig. 4B) implies AEG-1-induced augmentation of translation and protein stability. These observations suggest that translational regulation might be an important mechanism by which AEG-1 promotes de novo lipogenesis. AEG-1 has already been ascribed as a potential RNA-binding protein. (39) RNA immunoprecipitation followed by mass spectrometry identified Fasn mRNA to interact with AEG-1 in endometrial cancer cells, although the consequence of this interaction was not further analyzed. (39) It will be intriguing to further analyze the role of AEG-1 in regulating protein translation and ribosomal biogenesis.
A very important aspect of our study is the profound efficacy of PAMAM-AEG-1si to provide protection from HFD-induced steatosis. To our knowledge, this is the first demonstration that nanoparticle-mediated targeting of a specific gene provides therapeutic benefit in a NASH model. For liver diseases, RNA interference might be a useful strategy given that intravenously injected payload will go directly to the liver, thus ensuring high target organ delivery. A phase I trial utilizing intravenous administration of lipid-nanoparticleconjugated siRNA for vascular endothelial growth factor (VEGF) and kinesin spindle protein in cancer patients showed complete regression of metastatic lesion in the liver. (40) The success of this clinical trial provides an important precedent for the use of nanoparticles in the treatment of liver diseases and as such suggests that PAMAM-AEG-1si may be a plausible strategy to counteract NASH progression and needs to be further evaluated for potential translational application.
